Abstract
Abstract Purpose The use of anti‐glaucoma medications is often associated with ocular adverse reactions. These undesirable effects may lead to reduced quality of life, poor adherence or even treatment discontinuation in patients with glaucoma. This presentation summarizes currently available data relating to the effect of topical anti‐glaucoma preparations on the ocular surface. Results Anti‐glaucoma medications most commonly contain benzalkonium chloride (BAK) as a preservative. In vivo animal studies together with in vitro experiments have demonstrated various dose dependent adverse effects of BAK. Clinical studies have also shown an increased incidence of adverse events associated with BAK and have demonstrated that withdrawal of the preservative reduces these effects. Conclusion Collectively, these data suggest that use of preservative‐free anti‐glaucoma treatments have clinically relevant benefits for patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
